小剂量多西他赛单药维持治疗老年晚期非小细胞肺癌的临床观察

Clinical study of docetaxel lower-agent in the maintenance treatment of elderly patients with advanced non-small cell lung cancer

目的观察多西他赛小剂量维持化疗治疗老年晚期非小细胞肺癌(NSCLC)的疗效、临床受益反应(CBR)及不良反应。方法 42例经病理学或细胞学确诊的老年晚期NSCLC患者(≥60岁),应用多西他赛20mg/m2,静脉滴注,第1,8天给药,每21d为1周期;对照组给予最佳支持治疗(BSC)。结果多西他赛治疗组有效率(RR)为26.19%,中位缓解时间为6.9月,中位肿瘤进展时间(TTP)为5.8月,中位生存期(OS)为11.2月,1年生存率为40.2%;对照组RR为0,中位TTP为2.8月,中位OS为5.1月,1年生存率为9.6%。治疗组CBR较对照组有明显提高(P<0.01)。治疗组药物不良反应较轻,无因不良反应需停药者。结论多西他赛小剂量单药维持治疗老年晚期NSCLC疗效明确,不良反应较轻,可明显改善患者生活质量。

Objective To observe the efficacy, clinical benefit response (CBR) and drug-related toxicity of low-dose docetaxel in the maintenance treatment of elderly patients with advanced non-small cell lung cancer(NSCLC). Methods Forty-two elderly patients with histologically or cytologically diagnosed advanced NSCLC were treated with docetaxel infused on the first and 8th day at a dose of 20 mg/m2 , with 21 d as one cycle. Control group(n=53) received best supportive care(BSC). Results The response rate(RR) of docetaxel group was 26.19%, the median duration of response was 6.9 months, median time to tumor progression (TTP) was 5.8 months, the median overall survival time(OS) was 11.2 months and the 1-year survival rate was 40.2%. RR in control group was 0, the median TTP was 2.8 months, the median OS was 5.1 months and the 1-year survival rate was 9.6%. As compared with control group, CBR of docetaxel group was improved significantly(P<0.01). The toxicity of docetaxel was mild and no one stopped the medicine. Conclusions Low-dose docetaxel lower-agent is an effective drug in the maintenance treatment of elderly patients with advanced NSCLC, the toxicity can be well acceptable. Docetaxel can improve the quality of life and all patients have well compliance and tolerability.